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Purpose: It is still technically difficult to collect high purity cancer cells from tumor tissues, which contain
noncancerous cells. We hypothesized that xenograft models of NOG mice expressing enhanced green fluorescent
protein (eGFP), referred to as NOG-EGFP mice, may be useful for obtaining such high purity cancer cells for detailed
molecular and cellular analyses.
Methods: Pancreato-biliary cancer cell lines were implanted subcutaneously to compare the tumorigenicity
between NOG-EGFP mice and nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice. To obtain
high purity cancer cells, the subcutaneous tumors were harvested from the mice and enzymatically dissociated into
single-cell suspensions. Then, the cells were sorted by fluorescence-activated cell sorting (FACS) for separation of
the host cells and the cancer cells. Thereafter, the contamination rate of host cells in collected cancer cells was
quantified by using FACS analysis. The viability of cancer cells after FACS sorting was evaluated by cell culture and
subsequent subcutaneous reimplantation in NOG-EGFP mice.
Results: The tumorigenicity of NOG-EGFP mice was significantly better than that of NOD/SCID mice in all of the
analyzed cell lines (p< 0.01). Sorting procedures enabled an almost pure collection of cancer cells with only slight
contamination by host cells. Reimplantation of the sorted cancer cells formed tumors again, which demonstrated
that cell viability after sorting was well maintained.
Conclusions: This method provides a novel cancer sampling system for molecular and cellular analysis with high
accuracy and should contribute to the development of personalized medicine.
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Cancer xenograft models of immunodeficient mice are
widely applied in various cancer research areas. Recently,
xenografted human tumors are commonly used for pre-
clinical drug testing, including biomarker discovery. [1,2]
It has been reported that there is a close correlation be-
tween the effects in xenografts and clinical outcomes, in
terms of both drug resistance and sensitivity. [3] An
eventual goal of such preclinical studies using mouse* Correspondence: masamichi@surg1.med.tohoku.ac.jp
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reproduction in any medium, provided the orxenograft models is the realization of personalized medi-
cine. Molecular analyses using clinical specimens or
xenografted tumors are essential in research for persona-
lized medicine, and high purity samples of sufficient vol-
ume are necessary for precise analyses. In general,
mouse xenografts are superior to clinical specimens be-
cause of the abundance and renewability of the tumor
samples.
Tumors consist of two components, i.e. cancer cells
and stroma. Stromal cells derived from murine cells
within the xenografted tumors. Even though tumor tissue
acquired from patients is transplanted, human stromal
cells are ultimately replaced by murine stromal cells [4].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cise analyses of cancer cells using tumor tissue. Although
stromal cells need to be removed from tumor tissue as
much as possible to obtain accurate results, it is still tech-
nically difficult to collect high purity cancer cells without
contamination by stromal cells. As technologies of com-
prehensive analyses (e.g., high-resolution microarray, next-
generation sequencing and proteomics) are progressing
rapidly, high purity samples uncontaminated by stromal
cells are necessary for such advanced technology. There-
fore, it is very important to establish a method of separat-
ing cancer cells and stromal cells clearly and collecting
cancer cells uncontaminated by stromal cells.
On the other hand, athymic nude mice, nonobese
diabetic/severe combined immunodeficiency (NOD/
SCID) mice or NOD.Cg-Prkdcscid Il2rgtm1Sug/ShiJic
(NOG) mice are routinely used for mouse xenograft
models of cancer. Among these types of mice, NOG mice
show the most severe immunodeficient state. Machida
and colleagues have reported that NOG mice have higher
susceptibility to xenografted tumors than other immuno-
deficient mice [5]. Thus, NOG mice are very useful for
the transplantation of tumor tissue.
In 2008, Niclou and colleagues reported that NOD/
SCID mice with ubiquitous expression of enhanced
green fluorescent protein (eGFP) were useful for the
clear separation of tumor cells and mouse stromal cells
in subcutaneous xenografted tumors by fluorescence
activated cell sorting (FACS), and demonstrated that the
contamination by stromal cells after the removal of
eGFP-expressing cells was slight. [6] Meanwhile, Sue-
mizu et al. generated NOG mice expressing eGFP ubi-
quitously (NOG-EGFP) and clarified that NOG and
NOG-EGFP mice have equivalent immunodeficient
states. [7] However, there are no reports to study cancer
xenograft of NOG-EGFP mice.
In this study, we hypothesized that NOG-EGFP mice
are potentially useful for the collection of cancer cells
without contamination by stromal cells and would also
have the advantage of easy engraftment. Here we com-
pare the tumorigenicity between NOG-EGFP and NOD/
SCID mice and show the degree of contamination by
stromal cells after removal of eGFP-expressing cells in
the xenografted tumors of NOG-EGFP mice by FACS.
Furthermore, we demonstrate the viability of the col-




All animal experiments conformed to the guidelines of
the Institutional Animal Care and Use Committee of
Tohoku University and were performed in accordance
with the Guide for the Care and Use of LaboratoryAnimals of Tohoku University. The protocol was
approved by the Ethics Review Committee of Tohoku
University.
Animals
6 week-old female NOG-EGFP (formally, NOD.Cg-
PrkdcscidIl2rgtm1SugTg (Act-eGFP) C14-Y01-FM1310sb/
ShiJic) mice and NOG mice were kindly provided by
Central Institute for Experimental Animals (Kawasaki,
Japan). NOD/SCID mice were purchased from CLEA
Japan, Inc. (Tokyo, Japan). Female heterozygous NOG-
EGFP mice were mated with male NOG mice in order
to breed the NOG-EGFP mice under the permission of
Central Institute for Experimental Animals. Since their
offspring were NOG mice or NOG-EGFP mice, the
fluorescence of NOG-EGFP mice was confirmed by a
hand-held UV lamp (COSMO BIO, Tokyo, Japan).
Thereafter, NOG-EGFP mice were used in the experi-
ments. The animals were housed under pathogen-free
conditions on a 12-hour light cycle and with free access
to food and water.
Cell culture
Human pancreatic cancer cell lines (MIA Paca2 and
AsPC-1) and human cholangiocarcinoma cell lines
(HuCCT1 and TFK-1) were obtained from the Cell Re-
source Center for Biomedical Research of Tohoku
University. HuCCT1, TFK-1 and AsPC-1 were cul-
tured in RPMI-1640 media (Sigma-Aldrich, MO, USA)
with 10% heat-inactivated fetal bovine serum (FBS)
(SAFC Biosciences, MO, USA) and 1% penicillin/
streptomycin (P/S) (Gibco/Life Technologies, CA,
USA) at 37°C in an atmosphere of 5% CO2 and 95%
air. Dulbecco modified Eagle medium (DMEM)
(Gibco/Life Technologies) was used for culture of MIA
PaCa2 cells.
Image acquisition
We confirmed that organs and cells obtained from
NOG-EGFP mice could be fluorescently visualized. In
detail, after euthanizing NOG-EGFP mice, internal
organs were placed on a tray and imaged using an IVISW
Spectrum system (Caliper Life Sciences, MA, USA). Skin
fibroblasts of NOG-eGFP mice were cultured in RPMI-
1640 media with 10% FBS and 1% P/S. Subsequently,
cultured fibroblasts on dishes were visualized using a
Keyence BZ-9000 fluorescence microscope (Keyence
Corporation, Osaka, Japan).
Cell transplantation in NOG-EGFP and NOD/SCID mice
5 × 105 cells in a total volume of 100 μl media were
injected subcutaneously into each side of the lower back
of 6-8-week-old NOG-EGFP mice and NOD/SCID mice.
Tumor size was measured with digital calipers (A&D,
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mined using the following formula [8]:
tumor volume ¼ length  width2 =2
Patient-derived cancer xenografts
Resected specimens of pancreatic cancer tissue were cut
into 2–3mm3 pieces in antibiotic-containing RPMI-1640
media. Under anesthesia with pentobarbital (Abbott La-
boratories, IL, USA), and sevoflurane (Maruishi Pharma-
ceutical, Osaka, Japan), the pieces of the tumors were
implanted subcutaneously into each side of the lower
back in 6–8–week-old female NOG-EGFP mice. Tumors
were harvested upon reaching a volume of 1,500 mm3
and provided for immunohistochemistry.Figure 1 Confirmation of eGFP expression in NOG-EGFP mice. A) NOG
B) Representative photos of internal organs of NOG-EGFP mice. The fluores
C) Skin fibroblasts of NOG-EGFP mice cultured on the dishes were fluoresc
derived pancreatic cancer xenografts in NOG-EGFP mice. D-a) H&E staining
expressing cells are seen in the stroma. D-c) eGFP positive cells visualized u
with of Figure 1Db.Immunohistochemistry
Subcutaneous tumors of NOG-EGFP xenografts were
fixed in 10% formalin before embedded in paraffin. After
blocking, immunohistochemistry for eGFP was per-
formed using a rabbit anti-GFP (ab290, Abcam, MA
USA) at a dilution of 1:1000 incubated for 1hour at 25°C.
A horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG (Nichirei Biosciences, Tokyo, Japan) was used
as the secondary antibody. Peroxidase visualization was
done using 3,3'-Diaminobenzidine (DAB). All techniques
including H&E staining were performed by Animal Path-
ology Platform, Biomedical Research Core of Tohoku
University Graduate School of Medicine.
Cell sorting and phenotyping of murine stromal cells
TFK-1 xenografts were used in this experiment. Freshly
isolated subcutaneous tumors of NOG-EGFP mice were-EGFP mice were fluorescently visualized under a hand-held UV lamp.
cence was detected in all internal organs with IVISW spectrum system.
ent under the fluorescence microscope. D) Histology of patients-
. D-b) immunohistochemistry of the anti-eGFP antibody. eGFP-
nder the fluorescence microscope are seen in the stroma, concordant
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incubation in RPMI-1640 media containing collagenase
(Worthington Biochemical, NJ, USA) for 30 min at 37°C.
After incubation, the cell suspension was filtered through a
100-μm cell strainer. The cells were resuspended in phos-
phate buffered saline (PBS) and sorted on a fluorescence-
activated cell sorter (FACS Aria TM II Cell Sorter, BD
Biosciences, Erembodegem, Belgium) on the basis of
single-cell viability and the presence of GFP. For immuno-
phenotyping, cells were incubated for 30 min at room
temperature with conjugated antibodies against mouse
CD31, CD90, CD49b, CD14, CD11c (CD31: 561410, CD90:
553007, CD49b: 553858, CD14: 560636 and CD11c:
560583, BD Biosciences) or conjugated isotype controls
(APC-CyTM7 (Rat IgG1, κ)-560534, Alexa-Flour700 (Ham-
ster IgG, λ1): 560555, APC (Rat IgG2a, κ): 53932, PE (Rat
IgM, κ): 553943, PE-CyTM7 (Rat IgG2a, κ): 552867, BD
Biosciences), as previously reported [6] . Analyses were per-
formed on a FACS Aria TM II Cell Sorter (BD Biosciences).
Viability of sorted cancer cells
Xenografted tumors of TFK-1 cells in NOG-EGFP mice
were harvested and separated into cancer cells andFigure 2 Tumorigenicity was compared between NOG-EGFP mice and
A) TFK-1, B) HuCCT1, C) MIAPaCa2 and D) AsPC-1. A total of 5.0 × 105 cells
mice showed a significantly higher tumorigenic potential than that of NODstromal cells by FACS as described above. Collected
TFK-1 cells were cultured on dishes and subsequently
reimplanted in NOG-EGFP mice. In order to confirm
the effect of removal of eGFP-expressing cells, the sub-
cutaneous tumors of TFK-1 cells were provided for pri-
mary cell culture without FACS sorting as a control.
Statistical analysis
Data were presented as the mean ± S.E. Statistical signifi-
cance was determined by Mann–Whitney U test per-
forming using GraphPad Prism for Windows version
5.02. Differences between experimental groups were
considered significant when the p-value was <0.05.
Results
Confirmation of eGFP expression in NOG-EGFP mice
Green fluorescence was detected in the NOG-EGFP
mice by a hand-held UV lamp (Figure 1A). Almost all
internal organs showed green fluorescence in the im-
aging instrument (Figure 1B). The fluorescence of skin
fibroblasts was visible using a fluorescence microscope
(Figure 1C). Histological findings revealed eGFP-
expressing cells (shown as DAB-positive cells in FigureNOD/SCID mice using the pancreato-biliary cancer cell lines.
was injected into each mouse (n = 6). ** denotes P< 0.01. NOG-EGFP
/SCID mice in all cell lines (p< 0.01).
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of the xenografted tumors, whereas cancer cells did not
show eGFP expression (Figure 1Db-c). Based on the
findings mentioned above, expression of eGFP on NOG-
EGFP mice was confirmed.
Comparison of tumorigenic potential between NOG-EGFP
and NOD/SCID mice
Human pancreatic cancer cell lines (MIA PaCa2 and
AsPC-1) and human cholangiocarcinoma cell lines (TFK-
1 and HuCCT1) were inoculated into NOG-EGFP mice
and NOD/SCID mice for comparison of the tumorigenicContamination rate of 
stromal cells in co
Phenotypic markers





Figure 3 The FACS analysis was performed after single-cell suspensio
of NOG-EGFP mice. A) Two subpopulations indicating the cancer cells an
cancer cells were dyed with phenotypic markers to evaluate the contamina
are shown as representative data of the phenotypic markers. B) The contam
among the collected cancer cells are summarized as a table; note that onlypotential. The tumorigenic potential of the NOG-EGFP
mice was significantly superior (p < 0.01) to that of the
NOD/SCID mice in all cell lines (Figure 2A-D).
Separation of cancer cells and stromal cells
A single-cell suspension was obtained by enzymatic dis-
sociation from the xenografted tumors of TFK-1 cells.
The cancer cells and the GFP-expressing cells were
sorted using FACS. FACS analysis showed two subpopu-
lations clearly enabling us to separate the cancer cells
and the GFP-expressing cells (Figure 3A). Then, the sub-
population of cancer cells was collected for phenotypingphenotypic markers for 
llected cancer cells  






n obtained by enzymatic dissociation from xenografted tumors
d eGFP-expressing cells were clearly distinguished. The collected
tion rate of host cells in the collected cancer cells. Results of CD11c
ination rates of the phenotypic markers for murine stromal cells
a few host cells are contaminated.
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CD11c are specific markers suggesting the existence of
endothelial cells, fibroblasts, natural killer cells, macro-
phage and dendritic cells, respectively. The percentages
of mouse CD31, CD90, CD49b, CD14 and CD11c posi-
tive cells in the subpopulation of the cancer cells were al-
most below the detection level (0.9%: CD31; 0.4%: CD90;
1.6%: CD49b; 1.7%: CD14 and 0.4%: CD11c (Figure 3B).
These results demonstrated that the accuracy of the sep-
aration of the cancer cells and the host cells in this study
was the same as in the previous report [6].
Cell viability after FACS sorting
Cancer cells collected from TFK-1 xenografts of NOG-
EGFP mice by FACS were able to grow on the dishes
(Figure 4A). Few fluorescent cells were detectable amongFigure 4 In order to determine the cell viability, the cancer cells were
reimplanted into NOG-EGFP mice. A) Left panel (experimental): The fluo
on the dishes under the fluorescent microscope. Right panel (control): Dire
were detectable in some areas under the fluorescent microscope. Black arr
sorting were able to grow in the NOG-EGFP mice. Tumorigenicity of the so
cells shown in Figure 2A. A total amount of 5.0 × 105 cells was injected intothe collected cancer cells (experimental) on the dishes,
whereas the unsorted cancer cells (control) showed a
mixture of fluorescent and non-fluorescent cells
(Figure 4A). These results demonstrated that FACS sort-
ing could completely separate cancer cells and stromal
cells. Subsequent reimplantation after cell culture
showed that the sorted cancer cells had tumorigenic
ability (Figure 4B). Since the period from inoculation to
beginning of growth was longer in the sorted TFK-1cells
than in the unsorted TFK-1 cells (Figure 4B), the viabil-
ity of the sorted cells might have been lower than that of
the unsorted cells.
Discussion
The aim of the present study was to develop methods
for separating mice-xenografted human cancer cellscultured on dishes after FACS sorting and subsequently
rescent cells were invisible among the collected cancer cells cultured
ctly cultured cells from the xenografted TFK-1 tumors. Fluorescent cells
ows indicate eGFP-expressing cells. B) TFK-1 cells cultured after FACS
rted TFK-1 cells was directly compared with that of the unsorted TFK-1
each mouse (n = 6).
Shima et al. Journal of Experimental & Clinical Cancer Research 2012, 31:55 Page 7 of 7
http://www.jeccr.com/content/31/1/55from host cells by FACS with minimal amount of con-
tamination and also to maintain the cell viability for sub-
sequent analyses. For this purpose, we have developed
techniques that employ NOG-EGFP mice.
To date, fluorescent immunodeficient mice, i.e. GFP
nude mice [9], NOD/SCID EGFP mice [6] and NOG-
EGFP mice [7], have been established. The previous
reports showed that fluorescent mice were very useful
to study the details of tumor-stroma interaction [10-12].
Recently, Niclou and colleagues reported the almost
complete separation of cancer cells and host cells using
xenografted tumors of a glioma cell line in NOD/SCID
EGFP mice. Based on this report, we evaluated the con-
tamination rate of murine stromal cells among each cell
type collected cancer cells. Our results showed similar
contamination rates to those of the previous report and
suggest that fluorescent mice would be very useful for
the separation of cancer cells from host cells. However,
the purity of the separation might be different in tumor
type and implantation site since content rate of stromal
cells varies in them. Further studies including orthoto-
pic models of several organs and use of other tumor
types are needed to evaluate the purity of separation.
We also demonstrated that that sorted cancer cells were
able to grow in vitro and in vivo. One of the advantages
is that the tumor cells start to grow significantly earlier
in NOG-EGFP mice than in NOD/SCID mice. Our
present results provide a novel way of employing of col-
lected cancer cells for to various subsequent analyses. In
the report of the NOD/SCID EGFP xenografts, cancer
cells labeled with another type of fluorescence were
used for the separation study [6]. The present study
suggests that fluorescent labeling of cancer cells is not
necessary for the separation of cancer cells and host
cells.
On the other hand, this method is applicable for the
collection of not only cancer cells but also stromal cells.
The methodology using fluorescent mouse xenografts
might usefully contribute to studies of cancer stromal
cells.
In conclusion, NOG-EGFP has high potential utility for
complete separation of cancer cells and stromal cells with
minimal contamination, if any, from xenografted tumors.
Further studies are needed to establish a solid method-
ology for the separation and collection of stromal/cancer
cells, and the use of NOG-EGFP mice for this is very
promising.
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